DUBLIN--(BUSINESS WIRE)--The "Alport Syndrome Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.
Alport Syndrome Pipeline Analysis report covers 5 drugs currently in different phases of development.
The report provides Alport Syndrome treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.
Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Major industry players profiled as part of the report are Ember Therapeutics, Foresee Pharmaceuticals Co., Ltd., Reata Pharmaceuticals, Inc., Regulus Therapeutics Inc. and Variant Pharmaceuticals, Inc.
Key Topics Covered:
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
3. Executive Summary
4. Market Dynamics
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
18.104.22.168.1. Drug Profiling
22.214.171.124.2. Strategic Developments
126.96.36.199.3. Clinical trials
188.8.131.52.4. Clinical trial results
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
- Ember Therapeutics
- Foresee Pharmaceuticals Co., Ltd.
- Reata Pharmaceuticals, Inc.
- Regulus Therapeutics Inc.
- Variant Pharmaceuticals, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/25q3th/alport_syndrome?w=4